Cubist Pharmaceuticals to Commence Quarterly Conference Calls & Webcasts; Second-Quarter Earnings to be Released on August 5, 2002.Business Editors and Health/Medical Writers BIOWIRE2K LEXINGTON Lexington. 1 City (1990 pop. 225,366), seat of Fayette co., N central Ky., in the heart of the bluegrass region; inc. 1832, made coextensive with Fayette co. 1974. , Mass.--(BW HealthWire)--Aug. 1, 2002 Cubist Pharmaceuticals, Inc. (Nasdaq:CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ) invites shareholders and members of the financial and media communities to attend its quarterly conference call and webcast, following the release of second-quarter earnings on August 5, 2002. Commencing with this inaugural call and webcast, Cubist will hold quarterly conference calls and webcasts on a regular basis going forward. Detailed information for the second quarter event follows.
***************CONFERENCE CALL & WEBCAST INFORMATION******************
WHEN: Monday August 5, 2002 at 10:00 am ET
DOMESTIC & CANADA CALL-IN: (800) 915-4836
INTERNATIONAL CALL-IN: (973) 317-5319
CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CBST&script=
1020&item_id=ew,651352,1&layout=6
Replay will be available for 30 days via the Internet
**********************************************************************
Cubist's third-quarter 2002 earnings release, conference call and webcast are expected to occur on November November: see month. 5, 2002. For information on earnings releases, conference calls, webcasts and other upcoming events, please visit the Calendar under the Corporate Info section of Cubist's website at www.cubist.com. Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel pharmaceuticals to combat serious and life-threatening Adj. 1. life-threatening - causing fear or anxiety by threatening great harm; "a dangerous operation"; "a grave situation"; "a grave illness"; "grievous bodily harm"; "a serious wound"; "a serious turn of events"; "a severe case of pneumonia"; "a life-threatening infections. Cubist is evaluating the safety and efficacy of Cidecin(R) (daptomycin Daptomycin is a novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms. It is a naturally-occurring compound found in the soil saprotroph Streptomyces roseosporus. for injection) in the EDGE(TM) (Evaluation of Daptomycin against Gram-positive gram-positive /gram-pos·i·tive/ (-poz´it-iv) retaining the stain or resisting decolorization by alcohol in Gram's method of staining, a primary characteristic of bacteria whose cell wall is composed of peptidoglycan and teichoic acid. Entities) clinical trial program and has broadened its pipeline to include multiple pre-clinical drug candidates. The Company is engaged in strategic partnerships with Novartis Novartis International AG (NYSE: NVS) is a multinational pharmaceutical company based in Basel, Switzerland that manufactures drugs such as diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Pharma AG for the discovery and development of novel antiinfectives and with Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. for the commercialization of daptomycin in Europe. Cubist is headquartered in Lexington, MA and has operations in Vancouver, BC, Canada and Slough Slough (slou), city (1991 pop. 106,341) and borough, central England. After World War I, the residential city and its outlying area underwent rapid industrial development, owing in part to its proximity to London. , UK. Cubist Safeharbor Statement Statements contained herein that are not historical fact may be forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in the Company's recent SEC filings. Cidecin(R) and EDGE(TM) are trademarks of Cubist Pharmaceuticals, Inc. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion